Aion Therapeutic, Inc. Announces the Appointment of Dr. Herbert Fritsche, Former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at the University of Texas, MD Anderson Cancer Center in Houston, Texas as Chief Science Officer
Dr. Fritsche has also been appointed Chief Science Officer of AI Pharma, a wholly-owned subsidiary of Aion Therapeutic
Toronto, Ontario–(Newsfile Corp. – September 10, 2020) – Dr. Fritsche is a world-renowned Clinical Chemist and former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas, MD Anderson Cancer Center in Houston, Texas for 41 years.
He has published over 200 peer-reviewed scientific papers, invited articles and book chapters, and participated in the validation and FDA clearance process for most every commercial serum cancer marker currently in use in the United States. Dr. Fritsche holds 3 patents and 2 patents pending.
Additionally, Dr. Fritsche served as an invited consultant/advisor to the Food and Drug Administration, the National Cancer Institute, on the Laboratory Practice Guidelines Committee for the National Academy of Clinical Biochemistry, on the Editorial Board of six international scientific journals, and as a consultant to many major international diagnostic companies. Previously, he served on the Expert Panel for developing Tumor Marker Practice Guidelines for the American Society of Clinical Oncology (ASCO) from its inception until his retirement from MD Anderson Cancer Center.
Dr. Fritsche has served as President of the Clinical Ligand Assay Society (CLAS) and various national committees for both the Clinical Ligand Assay Society (CLAS) and American Association for Clinical Chemistry (AACC). He is a Fellow of the National Academy of Clinical Biochemistry.
His awards include the Johnson and Johnson Award for Outstanding Research and Contributions to Clinical Biochemistry from the National Academy of Clinical Biochemistry; Morton K Schwartz Award for Outstanding Achievements in the field of Cancer Diagnostics from AACC; Carl Jolliff Award for Lifetime Achievements in Immunology and Immunodiagnostics from the Immunology Division of the AACC; Morton K Schwartz Award for significant contributions to the development of cancer diagnostics from the New York Metro Division of the AACC.; Abbott-ISOBM Award for Outstand research in oncology; National Award for Contributions in Education by the AACC; Outstanding Clinical Chemist Award by the Texas Section of the AACC; the Dean’s Excellence Award from the University of Texas Graduate School of Biomedical Science; and the Distinguished Scientist Award from the CLAS.
Dr. Fritsche has lectured extensively for many years at international and national meetings of medical and professional societies and he is recognized internationally as an expert in the field of clinical chemistry, cancer diagnostics and laboratory medicine.
“Dr. Fritsche is a highly respected international authority in clinical chemistry and one of the world’s leading experts on tumor biomarkers. We are extremely honored that he, with his vast and unique experience, has agreed to become our Chief Science Officer,” stated Stephen D. Barnhill, MD. Executive Chairman of Aion Therapeutic. “Dr. Fritsche and I have been working together for more than 30 years on groundbreaking research utilizing artificial intelligence techniques primarily in the field of cancer diagnostics. We have co-authored numerous peer-reviewed publications and I look forward to working with Dr. Fritsche to continue our efforts to help patients globally.”
“Dr. Barnhill is a scientific visionary having brought together the fields of medicine and mathematics in a way that has and will continue to benefit patients worldwide. Dr. Barnhill is the earliest proponent of the use of artificial intelligence in medicine and he is considered an international expert in this new field of medicine. It has been a great pleasure to work with him on cutting edge scientific discovery for more than 30 years,” stated Dr. Herbert Fritsche. He added, “As a pioneer in artificial intelligence techniques in medicine and an inventor on more than 40 patents in this field, Dr. Barnhill’s contribution to the science of machine learning in medical applications is remarkable and unprecedented. I look forward to continuing our efforts to develop state-of-the-art technology and unique treatment formulations to help patients worldwide.”
Mr. Graham Simmonds, CEO of Aion Therapeutic, stated, “We welcome Dr. Fritsche to the growing team of international experts being established by Dr. Barnhill. We look forward to Dr. Fritsche’s expertise guiding our scientific efforts to create unique treatment formulations and intellectual property including the use of genomics in the development of personalized medicine therapies.”
About AI Pharma
Current AI techniques provides the backbone of our discovery methods, along with a unique and strategic geographic foundation in Jamaica, where the organization, in association with its Jamaican-based Cannabis License Authority (CLA) licensed medical cannabis partner, Apollon Formularies Jamaica, Ltd. has the requisite range of licenses and existing facilities to accommodate our discovery research.
- Jamaica is uniquely legal for medical cannabis via CLA approved licenses (which we have through our discovery partnership) and is one of the very few countries in the world where mushrooms (both edible and psychedelic) have never been made illegal and are openly sold. This allows AI Pharma to legally discover these unique combined formulations to build a large patent portfolio of blocking patents and products while most of the rest of the world is legally limited in this type of discovery.
- AI Pharma has a cultivation facility that is currently being prepared for mushrooms and will be operational in approximately sixty days.
- AI Pharma has an R&D facility, as well as, a processing laboratory to prepare mushroom extracts in their distilled research and treatment ready form.
- AI Pharma has leased space at Doc’s Place International, an award winning (recently ranked #1 in the world by Edibles Magazine) health and wellness resort in Negril, Jamaica for medical cannabis patients that will now also be utilized for AI Pharma’s patients as a treatment centre for psilocybin and combined psilocybin/cannabis based therapies.
About Aion Therapeutic Inc.
Aion Therapeutic Inc. (formerly, Osoyoos Cannabis Inc.) has a joint-venture agreement with a private, vertically-integrated licensed producer under the Cannabis Act (Canada) to offer contract tolling extraction services to third-party businesses. Additionally, the Company recently acquired 1196691 B.C. Ltd. d/b/a “PCAI Pharma” (www.pcai.ca) and its wholly-owned subsidiary AI Pharmaceuticals Jamaica Limited, a private corporation incorporated and operating under the laws of Jamaica. The business of AI Pharma involves, research and development, treatment, data mining and state-of-the-art artificial intelligence (machine learning) techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals utilizing compounds from cannabis (cannabinoids), psychedelic mushrooms (psilocybin), fungi (edible mushroom), natural psychedelic formulations (Ayahuasca), and other medicinal plants in a legal environment for this type of discovery. In addition, the Company is creating a strong international intellectual property portfolio related to their discoveries
For further information, please contact:
Aion Therapeutic Inc.
Executive Vice Chair & CEO
DISCLAIMER & READER ADVISORY
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “may”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, PCAI and AI Pharma. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the parties. The material factors and assumptions include regulatory and other third-party approvals, licensing and other risks. The forward-looking information contained in this release is made as of the date hereof and the parties are not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/63558
PharmaDrug Inc. Closes Transaction to Acquire First Smart Shop in the Netherlands and Now Initiates Major Push to Acquire Best of Breed High Traffic Locations
Toronto, Ontario–(Newsfile Corp. – September 21, 2020) – PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF) (“PharmaDrug” or the “Company“) is pleased to announce that its wholly-owned subsidiary Interrobang Ltd. (doing business as Super Smart) (“Super Smart“) has closed the transaction to acquire the retail establishment specializing in the sale of psychedelic products that was previously announced in the Definitive Agreement signed on August 14, 2020.
Super Smart has commenced a ten-day transition period with the previous owner to co-manage the store and the Company will take effective control on October 1, 2020. The Smart Shop is located in the Town of Tiel, a municipality in central Netherlands, and will serve as an initial platform for Super Smart to build out and refine its new smart shop vision and a springboard to develop its brand and operations. Over the past few months, Super Smart has laid much of the groundwork needed to purchase the first store and as such began developing the organizational structure that will enable the company to make several more purchases and scale up more efficiently. The work includes hiring a country manager, setting up corporate structures, template legal contracts, financial controls and bank accounts.
By taking control of its first store, Super Smart can now start working towards its modern vision for the Smart Shop that will focus on an elevated experience that should improve the current opinion regarding psychedelics amongst the Dutch population. This will include education, micro dosing products and a broader introduction of functional mushrooms. We will also look to work with producers to help modernize the branding of the products sold in our shops.
Our consolidation plans will unify several shops under one collective system. This includes the store design and back end functionality of the stores POS and CRM. This will allow us to collect valuable customer information that will help in creating a unique customer experience for each individual. There will be an important education component with a training program established for all customer facing employees.
Harry Resin, President of Super Smart, commented, “Education will be a foundation upon which our stores will be built. Having worked in the cannabis industry in The Netherlands for more than fifteen years and in California for the last 5 years, I plan on taking my experience in brand building and bringing that to Slim Winkel, our Dutch psychedelic retail concept.”
Acquisition and Store Expansion Strategy
Super Smart is still involved in active discussions with three additional smart shop owners in the Netherlands. While all three of those discussions are still ongoing, Super Smart is waiting to see the impact of the Covid pandemic on their sales to help determine the appropriate price. We believe the current resurgence should contribute to more attractive valuations. Additionally, the company has begun discussions with industry veterans who share in our vision and together we are contemplating opening new stores instead of acquiring existing ones. Vacancies are climbing across the country while rents are dropping in best of breed retail locations. We have already started looking for strategic locations in high traffic areas in top cities and towns. Additionally, management now believes that given the pandemic, it makes more sense to begin an online platform sooner.
About PharmaDrug Inc.
PharmaDrug Inc. is building an international controlled substance and natural medicine company with a focus on Europe. The Company owns 80% of Pharmadrug GmbH, a German medical cannabis distributor, with a Schedule I European Union narcotics license allowing for the importation and distribution of medical cannabis to pharmacies in Germany and throughout the EU. The Company also owns 100% of Super Smart, an early-stage retail company focused on consolidating the fragmented Dutch smartshop market. Smartshops are retail establishments in The Netherlands that specialize in the sale of psychoactive substances including psychedelic truffles.
For further information, please contact:
Daniel Cohen, Chairman and CEO
Caution Regarding Forward-Looking Information:
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Forward looking statements in this press release relate to the integration of the Smart Shop business, anticipated volume growth in the Company’s German business and the introduction by the Company of its own brand of medical cannabis. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons”, as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to locate additional supply of medical cannabis, owning interests in companies or projects that are engaged in activities currently considered illegal under United States federal law; changes in laws; limited operating history, reliance on management, requirements for additional financing, competition, hindering market growth; regulatory and political change. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64247
Is Ganja Gurus the New Weedmaps?
Canada’s Authority on Retail Cannabis and Delivery Services to Launch New Programs in Your Area in September 2020.
Edmonton, Alberta–(Newsfile Corp. – September 21, 2020) – Ganja Gurus is thrilled to announce they will be entering the Canadian market in September 2020 to provide services where others have recently failed. First impressions indicate an understanding of what is important to their consumers today. Not only are they able to satisfy the needs of their market, but in Accordance with their Mission Statement, they intend to give back to the community that has helped bring them to where they are today.
Moving forward from September 2020 Ganja Gurus intends to excel in the following for their consumers. Declan Stone, Co-Founder, “Choice and charity is our Motto. We will provide listings for dispensaries, retail storefronts, accessory shops, delivery services, mail order marijuana, local shops, head shops, accessories, etc.” As experienced users ourselves we understand the need to browse and appreciate the market when making our selections. Stone continues, “Having access to the big box stores enables us to meet your needs in any situation, but we want to go a step further for our consumers.”
They will not limit their users to certain retailers, instead allowing any licensed retailer to have a listing in the hope that the extra choice will allow for you to try something new, and support someone local. By joining the GanjaGurus community you gain the ability to help with the growth of companies who you may not hear of otherwise, and who greatly appreciate your support. Ultimately the choice lies in your hands, which is the beautiful thing when seeing the available options.
This supporting mentality does not stop there however. They are willing to take actions and not just use words. When you make the choice to use Ganja Gurus in selecting your next order, you are also choosing to side with a company actively giving back to their community. At Ganja Gurus they will be transparent in their charity actions. Stone concludes, “A portion of revenues generated through the site will be given directly to local charities, while another portion will be spent towards local advertising companies in order to give back to the communities that support us.”
If you would like more information regarding the launch of Ganja Gurus please contact The Ganja Gurus Team at firstname.lastname@example.org
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64107
Red Light Holland Grants Exclusive Access to a Prominent Canadian Production Company and Film Crew to Document the Company in the Netherlands
Toronto, Ontario–(Newsfile Corp. – September 21, 2020) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (“Red Light Holland” or the “Company“), an Ontario-based corporation positioning itself to engage in the production, growth and sale of its brand of magic truffles to the legal, recreational market within the Netherlands, is pleased to announce that it has granted a prominent Canadian production company and film crew exclusive access to provide video coverage of the activities of the Company and its Chief Executive Officer, Todd Shapiro, within the Netherlands, leading up to the Company’s previously announced iMicrodose product launch party (the “iMicrodose Launch Party“), scheduled on September 25, 2020, in Amsterdam, the Netherlands. Filming commenced on September 20, 2020 in Horst, the Netherlands (the location of the Company’s production and distribution facility) and will continue through to the iMicrodose Launch Party, covering, among other things, the iMicrodose brand, and the production and distribution facility.
“I’m so grateful for this production company reaching out and offering to document our journey. There’s a ton of hard work that is going on behind the scenes and if all goes according to plan – this will be another piece of earned Media, which hasn’t cost Red Light Holland a dime, to potentially highlight our Company, our tireless efforts and our iMicrodose brand to a much bigger widespread audience,” said Chief Executive Officer and Director of the Company, Todd Shapiro. “Out of respect to the production company’s intellectual property rights, which play a huge role in stimulating innovation and creativity – in this case focusing on Red Light Holland’s early magic truffles production facility, our iMicrodose product launch in the Netherlands, and our expected iMicrodose Launch Party – we’ve mutually agreed to hold off on providing more information for now. However, we look forward to sharing more details in early 2021 about this great exposure opportunity… Now let’s just hope my mug doesn’t get left on the cutting room floor!”
About Red Light Holland Corp.
The Company is an Ontario-based corporation positioning itself to engage in the production, growth and sale (through existing Smart Shops operators and an advanced e-commerce platform) of a premium brand of magic truffles to the legal, recreational market within the Netherlands, in accordance with the highest standards, in compliance with all applicable laws.
For additional information on the Company:
Neither the Canadian Securities Exchange (the “CSE”) nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements necessarily involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Readers are further cautioned that the assumptions used in the preparation of such forward-looking statements (including, but not limited to, the assumption that (i) the Company will be able to execute on its business plan, and will receive one or multiple licenses, permits, and authorizations from time to time necessary to execute on its business plan, (ii) the Company’s financial condition and development plans do not change as a result of unforeseen events, (iii) there will continue to be a demand, and market opportunity, for the Company’s product offerings, (iv) the Company will be able to establish, preserve and develop its brand, and attract and retain required personnel, (v) the Company will be successful in offering for sale the iMicrodosing packs as contemplated, on the terms and within the timelines anticipated by the Company, (vi) current and future economic conditions will neither affect the business and operations of the Company nor the Company’s ability to capitalize on anticipated business opportunities, (vii) the magic truffles currently being grown by the Company will be ready for harvest and distribution within the timelines anticipated by the Company, and (viii) the production company will commence and complete video coverage of the Company as contemplated, on the terms and within the timelines anticipated by the Company), although considered reasonable by management of the Company at the time of preparation, may prove to be imprecise and result in actual results differing materially from those anticipated, and as such, undue reliance should not be placed on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws. Forward-looking statements, forward-looking financial information and other metrics presented herein are not intended as guidance or projections for the periods referenced herein or any future periods, and in particular, past performance is not an indicator of future results and the results of the Company in this news release may not be indicative of, and are not an estimate, forecast or projection of the Company’s future results. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
Not for distribution to United States newswire services or for dissemination in the United States.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64217
Cannabis4 weeks ago
Successful MustGrow Test Results: Efficacious Control of Canola Clubroot Disease in Greenhouse Soil
Cannabis3 weeks ago
3 Rivers Biotech to Establish Genetic Fingerprinting and Pathogen Testing Lab
Cannabis2 weeks ago
Rapid Screening Tests Are Still Struggling to Keep up with Demand
Cannabis3 weeks ago
DGDM’s Disruptive Pesticide Product Targeted to MJ Growers Passes Testing Trials During Pre-EPA Certification Period
Cannabis2 weeks ago
DGDM Provides Further Analysis of Specific Trial Testing Results of Its Disruptive Pesticide Product Targeted at MJ Growers
Cannabis3 weeks ago
Fernhill Beverage Branches Out for Success!
Latest News3 weeks ago
The Most Popular Online Casino Trends
Cannabis4 days ago
Sixth Wave Innovations Announces Collaborative “Green” Test Initiatives with Mining and Process Solutions (Australia)